title: β-Blocker-Associated Risks in Patients With Uncomplicated Hypertension Undergoing Noncardiac Surgery.
abstract: OBJECTIVE
  Perioperative β-blocker strategies are important to reduce risks of adverse events. Effectiveness and safety may differ according to patients' baseline risk.
  
  
  OBJECTIVE
  To determine the risk of major adverse cardiovascular events (MACEs) associated with long-term β-blocker therapy in patients with uncomplicated hypertension undergoing noncardiac surgery.
  
  
  METHODS
  Association study based on in-hospital records and out-of-hospital pharmacotherapy use using a Danish nationwide cohort of patients with uncomplicated hypertension treated with at least 2 antihypertensive drugs (β-blockers, thiazides, calcium antagonists, or renin-angiotensin system [RAS] inhibitors) undergoing noncardiac surgery between 2005 and 2011.
  
  
  METHODS
  Various antihypertensive treatment regimens, chosen as part of usual care.
  
  
  METHODS
  Thirty-day risk of MACEs (cardiovascular death, nonfatal ischemic stroke, nonfatal myocardial infarction) and all-cause mortality, assessed using multivariable logistic regression models and adjusted numbers needed to harm (NNH).
  
  
  RESULTS
  The baseline characteristics of the 14,644 patients who received β-blockers (65% female, mean [SD] age, 66.1 [12.0] years) were similar to those of the 40,676 patients who received other antihypertensive drugs (57% female, mean [SD] age, 65.9 [11.8] years). Thirty-day MACEs occurred in 1.3% of patients treated with β-blockers compared with 0.8% of patients not treated with β-blockers (P < .001). β-Blocker use was associated with increased risks of MACEs in 2-drug combinations with RAS inhibitors (odds ratio [OR], 2.16 [95% CI, 1.54-3.04]), calcium antagonists (OR, 2.17 [95% CI, 1.48-3.17]), and thiazides (OR, 1.56 [95% CI, 1.10-2.22]), compared with the reference combination of RAS inhibitors and thiazides. Results were similar for all-cause mortality. Risk of MACEs associated with β-blocker use seemed especially pronounced for patients at least 70 years old (number needed to harm [NNH], 140 [95% CI, 86-364]), for men (NNH, 142 [95% CI, 93-195]), and for patients undergoing acute surgery (NNH, 97 [95% CI, 57-331]), compared with patients younger than 70 years, women, and patients undergoing elective surgery, respectively.
  
  
  CONCLUSIONS
  Antihypertensive treatment with a β-blocker may be associated with increased risks of perioperative MACEs and all-cause mortality in patients with uncomplicated hypertension.
authors.affiliation: Cardiovascular Research Center, Gentofte Hospital, University of Copenhagen, Denmark.
authors.forename: Mads E
authors.initials: ME
authors.lastname: Jørgensen
authors.affiliation: Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Hlatky
authors.affiliation: Heart Center, Rigshospitalet, Copenhagen University, Denmark.
authors.forename: Lars
authors.initials: L
authors.lastname: Køber
authors.affiliation: Department of Anesthesiology, University of Wisconsin, Madison.
authors.forename: Robert D
authors.initials: RD
authors.lastname: Sanders
authors.affiliation: Department of Health Science and Technology, Aalborg University, Denmark.
authors.forename: Christian
authors.initials: C
authors.lastname: Torp-Pedersen
authors.affiliation: Cardiovascular Research Center, Gentofte Hospital, University of Copenhagen, Denmark6Danish Heart Foundation, Copenhagen, Denmark.
authors.forename: Gunnar H
authors.initials: GH
authors.lastname: Gislason
authors.affiliation: Department of Cardiothoracic Anesthesia, Rigshospitalet, Copenhagen University, Denmark.
authors.forename: Per Føge
authors.initials: PF
authors.lastname: Jensen
authors.affiliation: Cardiovascular Research Center, Gentofte Hospital, University of Copenhagen, Denmark.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Andersson
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D002423:Cause of Death / Q000639:trends; D003718:Denmark / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D013502:General Surgery; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000453:epidemiology; D057234:Preoperative Period; D011379:Prognosis; D057216:Propensity Score; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D020521:Stroke / Q000139:chemically induced* / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000319:Adrenergic beta-Antagonists